Individuals that have MMR mutations are typically predicted to account for 2%–5% of PCa cases (Ritch et al., 2020; Ye et al., 2020), and they are generally identified by their Gleason score 8 and de novo metastases (Dominguez-Valentin et al., 2016; Ye et al., 2020; Jiang et al., 2021; Graham and Schweizer, 2022). This evidence concerns the gene MRC1 and posterior cortical atrophy.